Business Context and Reporting Period
Company: ProQR Therapeutics N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Accounting Basis: International Financial Reporting Standards (IFRS)
Business Overview: ProQR is a pre-clinical stage biopharmaceutical company developing RNA-based therapeutics for severe genetic disorders. The company focuses on two lead product candidates: QR-010 for Cystic Fibrosis (CF) and QR-110 for Leber's Congenital Amaurosis (LCA). The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric (€ in thousands) | 2014 | 2013 |
|---|---|---|
| Other Income | 313 | 116 |
| Research & Development Costs | (10,267) | (2,569) |
| General & Administrative Costs | (6,507) | (786) |
| Operating Result | (16,461) | (3,239) |
| Net Loss | (12,127) | (3,253) |
| Cash and Cash Equivalents (Year End) | 112,736 | 4,129 |
| Total Assets | 115,247 | 4,504 |
| Total Liabilities | 5,843 | 4,593 |
| Shareholders' Equity | 109,404 | (89) |
| Outstanding Ordinary Shares | 23,338,154 | 6,108,152 |
Note: The 2014 Net Loss includes a significant non-cash foreign exchange gain of €4.334 million in finance income.
Material Changes vs. Prior Period
- Capital Raise: In September 2014, the company completed an Initial Public Offering (IPO) raising gross proceeds of approximately €87.2 million (net proceeds of €80.4 million). This resulted in a substantial increase in cash and cash equivalents from €4.1 million in 2013 to €112.7 million in 2014.
- Operating Expenses: Research and Development (R&D) costs increased 300% to €10.3 million, driven by increased staff (40 FTEs vs. 12 in 2013), GMP production of QR-010, and pre-clinical studies. General and Administrative (G&A) costs increased 728% to €6.5 million, largely due to costs associated with the IPO (€1.8 million) and public company compliance.
- Foreign Exchange: The company realized a net finance income of €4.3 million in 2014, primarily due to foreign exchange benefits on U.S. dollar-denominated cash balances, compared to a negligible expense in 2013.
- Equity Structure: Preferred shares issued in 2014 were converted to ordinary shares in connection with the IPO.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring significant losses for the foreseeable future. Based on current cash balances, the company believes it can fund operations through at least mid-2017.
- Clinical Development: The company plans to dose the first patient in a Phase 1b clinical trial for QR-010 in the first half of 2015. A proof-of-concept study is also planned for 2015. QR-110 is expected to enter clinical trials in 2016.
- Contingent Liabilities:
- CFFT Agreement: The company has an agreement with the Cystic Fibrosis Foundation Therapeutics (CFFT) to receive up to $3 million in grants. However, the first commercial sale of QR-010 will trigger a milestone payment of approximately $80 million to CFFT.
- Patent Licenses: The company has royalty and milestone obligations to Massachusetts General Hospital (MGH) and Radboud University Medical Center.
- Risks: Key risks include the failure of clinical trials, inability to obtain regulatory approval, dependence on third-party manufacturers, and the need for additional capital to fund operations and potential milestone payments. The company is an "emerging growth company" and a "foreign private issuer," subject to reduced disclosure requirements.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "mid-2017" funding estimate given the high burn rate (€14.5 million cash used in operating activities in 2014).
- Milestone Obligations: Review the specific terms of the CFFT agreement regarding the $80 million milestone payment and the company's ability to fund it upon commercialization.
- Foreign Exchange Impact: Assess the sustainability of the €4.3 million finance income, which significantly reduced the reported net loss and was driven by currency fluctuations rather than operations.
- Intellectual Property: Confirm the status of patent licenses with MGH and Radboud University, including milestone triggers and royalty rates.
- Clinical Timeline: Monitor the initiation of the Phase 1b trial for QR-010 in 2015 as a critical near-term catalyst.